Zhang Jia Jie Shi

Researchers are investigating treatments for HER2-positive advanced breast cancer in patients who have already received at least two prior anti-HER2 therapies. This Phase III clinical trial compares the effects and safety of TQB2930, a HER2 bispecific antibody drug, combined with chemotherapy, against trastuzumab combined with chemotherapy. The study aims to evaluate which treatment approach may better manage advanced breast cancer that has progressed despite prior therapies. Participants are randomly assigned to one of two groups. One group receives TQB2930 injection at 30 mgkg every three weeks along with a chemotherapy agent chosen by the investigator, with each treatment cycle lasting 21 days. The other group receives trastuzumab starting with an 8 mgkg dose followed by 6 mgkg every three weeks, combined with investigator-selected chemotherapy, also given in 21-day cycles. Chemotherapy options include drugs like Capecitabine, Gemcitabine, Vinorelbine, or Eribulin. Throughout the study, participants undergo regular assessments to monitor disease progression and treatment response, including scans and evaluations lasting about one to two years. The main outcome measured is progression-free survival as assessed by an independent review committee. Additional outcomes include overall survival, duration of response, tumor response rates, and safety monitoring for adverse events. Blood samples are collected at specific cycles to measure drug levels and immune responses. The study includes safety follow-up for 90 days after the last dose or until another anticancer treatment begins.

Researchers are evaluating treatments for adults with acute spontaneous supratentorial intracerebral hemorrhage ICH of 20mL or more. This trial compares early minimally invasive surgery combined with thrombolysis eMIST to best medical management. The goal is to assess which approach improves functional outcomes after stroke, measured by a blinded evaluation at 180 days using the modified Rankin Scale. Participants are randomly assigned to one of two groups one receives minimally invasive catheter evacuation followed by up to 10 doses of urokinase to help dissolve the clot the other group receives standard medical care. The intervention is given early after stroke onset, with randomization within 8 hours and treatment started within 4 hours after randomization. The study uses an adaptive design with ongoing assessment of sample size and outcomes. During the study, participants undergo assessments including brain imaging, functional outcome scales, and quality of life questionnaires at multiple time points up to 180 days. Researchers will monitor clot removal, mortality, daily living activities, and health-related quality of life. The trial includes follow-up visits to evaluate recovery and safety over time, supporting a thorough understanding of treatment effects and participant progress.